VYNE has 36-month beta value of 1.28. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VYNE is 12.03M, and currently, short sellers hold a 0.71% ratio of that float. The average trading volume of VYNE on April 25, 2024 was 103.12K shares.
VYNE) stock’s latest price update
VYNE Therapeutics Inc (NASDAQ: VYNE) has experienced a rise in its stock price by 10.78 compared to its previous closing price of 2.32. However, the company has seen a gain of 7.08% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-19 that BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.
VYNE’s Market Performance
VYNE’s stock has risen by 7.08% in the past week, with a monthly rise of 4.05% and a quarterly rise of 41.99%. The volatility ratio for the week is 8.61% while the volatility levels for the last 30 days are 9.24% for VYNE Therapeutics Inc The simple moving average for the past 20 days is -5.32% for VYNE’s stock, with a -18.62% simple moving average for the past 200 days.
Analysts’ Opinion of VYNE
Many brokerage firms have already submitted their reports for VYNE stocks, with H.C. Wainwright repeating the rating for VYNE by listing it as a “Buy.” The predicted price for VYNE in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on December 06, 2021 of the previous year 2021.
VYNE Trading at 6.71% from the 50-Day Moving Average
After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.56% of loss for the given period.
Volatility was left at 9.24%, however, over the last 30 days, the volatility rate increased by 8.61%, as shares sank -9.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.15% upper at present.
During the last 5 trading sessions, VYNE rose by +7.08%, which changed the moving average for the period of 200-days by -39.53% in comparison to the 20-day moving average, which settled at $2.70. In addition, VYNE Therapeutics Inc saw 10.30% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYNE starting from LEPORE PATRICK G, who purchase 13,000 shares at the price of $3.91 back on Nov 15 ’23. After this action, LEPORE PATRICK G now owns 36,472 shares of VYNE Therapeutics Inc, valued at $50,778 using the latest closing price.
Stock Fundamentals for VYNE
Current profitability levels for the company are sitting at:
- -69.01 for the present operating margin
- 1.0 for the gross margin
The net margin for VYNE Therapeutics Inc stands at -67.1. The total capital return value is set at -0.32. Equity return is now at value -46.40, with -40.27 for asset returns.
Based on VYNE Therapeutics Inc (VYNE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -118.42.
Currently, EBITDA for the company is -29.26 million with net debt to EBITDA at 1.04. When we switch over and look at the enterprise to sales, we see a ratio of 13.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.73.
Conclusion
To put it simply, VYNE Therapeutics Inc (VYNE) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
